Ascendis Pharma A/S (ASND) Stock AnalysisASNDAscendis Pharma A/S

Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ascendis Pharma (ASND) is currently a hold. The stock is trading at $225.25, which is below the analyst price target range of $273 to $312, indicating potential upside. However, the RSI is at 43.23, suggesting the stock is nearing oversold territory, but not yet a strong buy signal. The recent positive regulatory news for TransCon CNP could drive future growth, but insider selling has increased by 565.41%, indicating potential caution from insiders. The main risk is the recent 5-day change of -1.74%, reflecting short-term volatility.

6 analysts cover ASND: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 277.08.